Hemispherx Biopharma
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
600 Main St Ste 2, Riverton, New Jersey,...Phone Number
(407) 839-0095Website
www.hemispherx.netRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Hemispherx Biopharma
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companys approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia,...Explore more
Hemispherx Biopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemispherx Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Hemispherx Biopharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Hemispherx Biopharma launches new products
Check if Hemispherx Biopharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Hemispherx Biopharma has new funding data
Earning: See what the market has to say on Hemispherx Biopharma recently announced quarterly report
Hemispherx Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Hemispherx Biopharma
Click to see if Hemispherx Biopharma had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Hemispherx Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hemispherx Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hemispherx Biopharma.
Hemispherx Biopharma Tech Stack
A closer look at the technologies used by Hemispherx Biopharma
Most Recent Scoops
Award
Executive Move
Left Company
Executive Move
As previously announced, Adam Pascale, Chief Financial Officer has left the organization.
Executive Moves, Left Company
Left Company
Executive Move
Hemispherx Biopharma has announced Adam Pascale, Chief Financial Officer, will be retiring from the organization, effective September 15th, 2019.
Executive Moves, Left Company
Promotion
Executive Move
Ellen Lintal has been promoted from Vice President, Finance & Control to the role of Chief Accounting Officer.
Executive Moves, Promotion
Earnings
Earnings
Hemispherx Biopharma News & Media
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today provided an update on its ongoing efforts to develop an effective therapeutic for “Long COVID” with its investigational drug, Ampligen.AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced it will participate in the Solve M.E. Diagnostics signature event “Long COVID: Research, Policy, and Economic Impact,” being held virtually and in New YAIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hemispherx Biopharma
Sign Up For FreeTo access detailed company insights
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companys approved products include Alferon N Injection, an injectable formulation of natur... Read More
